0001209191-21-063200.txt : 20211105 0001209191-21-063200.hdr.sgml : 20211105 20211105170021 ACCESSION NUMBER: 0001209191-21-063200 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211104 FILED AS OF DATE: 20211105 DATE AS OF CHANGE: 20211105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOZE BARRY CENTRAL INDEX KEY: 0001619500 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 211385382 MAIL ADDRESS: STREET 1: C/O HORIZON PHARMA, INC. STREET 2: 520 EAST COOK ROAD, SUITE 520 CITY: DEERFIELD STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-04 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001619500 MOZE BARRY C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHEN?S GREEN DUBLIN L2 D02 E2X4 IRELAND 0 1 0 0 EVP, Chief Admin. Officer Ordinary Shares 2021-11-04 4 M 0 3000 22.14 A 78681 D Ordinary Shares 2021-11-04 4 M 0 443 11.81 A 79124 D Ordinary Shares 2021-11-04 4 M 0 72300 14.48 A 151424 D Ordinary Shares 2021-11-04 4 S 0 23382 110.17 D 128042 D Ordinary Shares 2021-11-04 4 S 0 15856 111.75 D 112186 D Ordinary Shares 2021-11-04 4 S 0 6151 112.60 D 106035 D Ordinary Shares 2021-11-04 4 S 0 17867 113.56 D 88168 D Ordinary Shares 2021-11-04 4 S 0 6763 114.43 D 81405 D Ordinary Shares 2021-11-04 4 S 0 5724 115.45 D 75681 D Stock Option (Right to Buy) 22.14 2021-11-04 4 M 0 3000 0.00 D 2025-03-22 Ordinary Shares 3000 162181 D Stock Option (Right to Buy) 11.81 2021-11-04 4 M 0 443 0.00 D 2024-09-11 Ordinary Shares 443 0 D Stock Option (Right to Buy) 14.48 2021-11-04 4 M 0 72300 0.00 D 2024-06-05 Ordinary Shares 72300 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.10 to $112.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.12 to $113.085 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.14 to $114.135 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.14 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.15 to $115.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested and exercisable. /s/ Miles W. McHugh, Attorney-in-Fact 2021-11-05